Independent research tool — not a government agency. Official notices govern.Refreshed
GrantsJunctionAmerican funding, sourcedMethodology
OpenResearch announcementOpportunity PAR-25-145

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

National Institutes of Health · Department of Health and Human Services

At a glance

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) is an open federal grant opportunity from the National Institutes of Health (Department of Health and Human Services). Applications are due January 7, 2028. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.393 (Cancer Cause and Prevention Research).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

  1. Nov 6, 2024Posted
  2. Jan 7, 2028Application deadlinenext date
  3. Feb 12, 2028Archived
Posted
Nov 6, 2024
Close date
Jan 7, 2028
Archive date
Feb 12, 2028
Award floor
Not specified
Award ceiling
Not specified
Est. total funding
Not specified
Expected awards
Not specified
Cost sharing
Not required
Funding instrument
Grant
Opportunity category
Discretionary

Typical awards for this program (SAM.gov listing for ALN 93.393, not this notice): Range: $927 to $3,046,580 Average: $568,686

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public colleges & universities
  • Federally recognized tribal governments
  • Public & Indian housing authorities
  • Native American tribal organizations
  • 501(c)(3) nonprofits
  • Nonprofits without 501(c)(3) status
  • Private colleges & universities
  • For-profit organizations (not small businesses)
  • Small businesses
  • Others (see notice)

Additional information on eligibility (from the notice)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Additional information from the agency ↗

Full announcement & documents

The full announcement has the complete rules — page limits, required attachments, evaluation criteria and any letter-of-intent dates. Files download directly from Grants.gov.

How to apply

0 of 8 done · progress saved in this browser

Assistance Listing

What is an ALN?

Reported obligations under ALN 93.393

Historical data · not a prediction
FY24$755M
FY25$835M
FY26$520M est.
Source: SAM.gov Assistance Listing 93.393. Program-wide totals, not awards from this specific opportunity.

Who was funded under ALN 93.393

Historical data · not a prediction

Since October 1, 2023, 3,097 grant awards had funding actions under Cancer Cause and Prevention Research, with 3,423 sub-awards passed on to other organizations. These are program-wide awards, not awards from this specific notice.

  1. THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER$87.6M
  2. DANA-FARBER CANCER INSTITUTE, INC.$68.4M
  3. SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH$57M
  4. THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK$52.3M
  5. UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL$49.4M
Recipients, states, recent awards and sub-awards →Source: USAspending.gov.

Agency contact (as published)

National Institutes of Health
grantsinfo@nih.gov
301-402-2541

Quick answers

When is the deadline for this opportunity?

According to the official notice, applications are due January 7, 2028. Confirm the deadline and submission time on Grants.gov before applying.

Who is eligible to apply for this opportunity?

The official notice names these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.

How do I apply for this opportunity?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity PAR-25-145), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.